The GLP-1 shortage spawned a compounding boom. As the FDA winds it down, semaglutide is left as three distinct things that share a molecule’s regulatory story but not a legal status — and a research vial is the most misunderstood of them.
Blueprint’s founder has run dozens of peptides through his body and his biomarkers. Ranked by evidence, his protocol separates the plausible from the speculative — and his most instructive move was quitting something that “felt” like it worked.
Retatrutide is a real phase III triple agonist that produced some of the largest weight-loss figures in trial history. The vial sold on a research-chemical site is not that drug — and here is the honest distinction.
In a few short years, peptides went from obscure lab reagents to the most-discussed molecules in longevity and biohacking culture. A look at why now — and why the hype has outrun the data.
On 20 April 2026, one of the world’s biggest podcasts told millions that Big Pharma is hiding a powerful peptide. We checked the science, line by line: where the episode is right, where it is clickbait, and where the honest evidence simply runs out.
On 1 June 2026, Huberman Lab spent a full episode on peptides. It was more careful than most of the internet. Here is what it covered — and how each claim holds up against the published research.
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.